Novartis to Acquire Excellergy for up to $2 Billion

Novotech to Acquire Agilex Biolabs from Healius to Expand Australian Bioanalytical Services

September 25, 2026

Healthcare Services

Novotech entered into an agreement to acquire Agilex Biolabs, an Adelaide-based Australian specialist bioanalytical laboratory business, from a wholly owned subsidiary of Healius. The deal is intended to expand Novotech’s laboratory capabilities in Australia and strengthen integrated clinical research and laboratory services for biotechnology and pharmaceutical clinical trial sponsors. Financial terms were not disclosed, and closing remains subject to customary regulatory conditions.

Novartis Acquires Myricx Bio (ADC NMTi Payload Platform) for Up to $1.5 Billion

July 7, 2026

Biotechnology

Sofinnova Partners’ portfolio company Myricx Bio has agreed to be acquired by Novartis in a deal valued at up to $1.5 billion, including $1.1 billion in cash upfront plus potential milestone payments. Myricx Bio is a UK-headquartered biotech developing NMTi payloads and lead ADC assets targeting B7-H3 and HER2 for solid tumors.

Eli Lilly to Acquire Vaccine Company for Up to $1.55 Billion

May 27, 2026

Biotechnology

Vaccine Company, Inc. announced it has entered into a definitive agreement to be acquired by Eli Lilly and Company in a deal valued at up to $1.55 billion, including upfront and milestone-based payments. The acquisition is intended to accelerate development of Vaccine Company’s next-generation in vivo nanoparticle (IVN) vaccine platform, led by a Phase 1-ready Epstein-Barr virus (EBV) vaccine candidate targeting infectious mononucleosis and longer-term EBV-linked diseases.

Eli Lilly and Company to Acquire Ventyx Biosciences

January 8, 2026

Pharmaceuticals

Eli Lilly and Company has entered into a definitive agreement to acquire Ventyx Biosciences for approximately $1.2 billion. The deal values Ventyx at $14.00 per share in cash and is expected to close in the first half of 2026, subject to shareholder and regulatory approvals.

Novartis AG to Acquire Avidity Biosciences in $12B Deal (with Precision Cardiology SpinCo)

October 26, 2025

Biotechnology

Novartis AG has entered into a definitive merger agreement to acquire Avidity Biosciences for $72.00 per share in cash, valuing Avidity at approximately $12.0 billion. The transaction follows the planned separation of Avidity’s early-stage precision cardiology programs into a new publicly traded company (“SpinCo”), which is expected to begin trading after the spin-off.

Novo Nordisk to Acquire Akero Therapeutics for Up to $5.2 Billion

October 10, 2025

Pharmaceuticals

Akero Therapeutics announced it has entered into a definitive agreement to be acquired by Novo Nordisk A/S in a transaction valued at up to $5.2 billion in cash. Under the terms of the deal, Akero shareholders will receive $54.00 per share at closing plus a non-transferable Contingent Value Right (CVR) that could pay an additional $6.00 per share contingent on full U.S. regulatory approval of efruxifermin (EFX) for compensated cirrhosis associated with MASH.